CN102574860A - 吡咯并[2,3-d]嘧啶化合物 - Google Patents

吡咯并[2,3-d]嘧啶化合物 Download PDF

Info

Publication number
CN102574860A
CN102574860A CN2010800461239A CN201080046123A CN102574860A CN 102574860 A CN102574860 A CN 102574860A CN 2010800461239 A CN2010800461239 A CN 2010800461239A CN 201080046123 A CN201080046123 A CN 201080046123A CN 102574860 A CN102574860 A CN 102574860A
Authority
CN
China
Prior art keywords
methyl
alkyl
hydrogen
amino
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800461239A
Other languages
English (en)
Chinese (zh)
Inventor
B·A·阿克
S·J·哈特曼
黄鸿志
E·J·雅各布森
M·A·普罗莫
S·G·沃尔夫森
谢进
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN102574860A publication Critical patent/CN102574860A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800461239A 2009-10-15 2010-10-01 吡咯并[2,3-d]嘧啶化合物 Pending CN102574860A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15
US61/252,039 2009-10-15
PCT/IB2010/054447 WO2011045702A1 (en) 2009-10-15 2010-10-01 Pyrrolo[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
CN102574860A true CN102574860A (zh) 2012-07-11

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800461239A Pending CN102574860A (zh) 2009-10-15 2010-10-01 吡咯并[2,3-d]嘧啶化合物

Country Status (29)

Country Link
US (1) US8633206B2 (enExample)
EP (1) EP2488524B1 (enExample)
JP (1) JP5629324B2 (enExample)
KR (1) KR20120083452A (enExample)
CN (1) CN102574860A (enExample)
AP (1) AP2012006192A0 (enExample)
AR (1) AR078635A1 (enExample)
AU (1) AU2010308028A1 (enExample)
CA (1) CA2776028C (enExample)
CL (1) CL2012000795A1 (enExample)
CO (1) CO6531451A2 (enExample)
CR (1) CR20120164A (enExample)
CU (1) CU20120059A7 (enExample)
DO (1) DOP2012000080A (enExample)
EA (1) EA201290147A1 (enExample)
EC (1) ECSP12011855A (enExample)
ES (1) ES2426407T3 (enExample)
IL (1) IL218802A0 (enExample)
IN (1) IN2012DN02577A (enExample)
MA (1) MA33670B1 (enExample)
MX (1) MX2012004379A (enExample)
NI (1) NI201200053A (enExample)
PE (1) PE20121077A1 (enExample)
PH (1) PH12012500583A1 (enExample)
TN (1) TN2012000146A1 (enExample)
TW (1) TWI398444B (enExample)
UY (1) UY32947A (enExample)
WO (1) WO2011045702A1 (enExample)
ZA (1) ZA201202718B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896946A (zh) * 2012-12-28 2014-07-02 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
CN105164133A (zh) * 2013-05-02 2015-12-16 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2，3-d]嘧啶衍生物
CN105008362B (zh) * 2013-02-22 2017-06-06 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
CN111499641A (zh) * 2019-01-30 2020-08-07 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
CN114025758A (zh) * 2019-07-01 2022-02-08 钱立刚 P2x7r拮抗剂
CN114761011A (zh) * 2019-08-26 2022-07-15 肯沃斯公司 用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物
CN115246833A (zh) * 2021-04-27 2022-10-28 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
BRPI1013559A2 (pt) 2009-03-23 2016-04-12 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011075334A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
PH12013502670A1 (en) 2011-08-12 2016-07-29 Nissan Chemical Ind Ltd Tricyclic heterocyclic compounds and jak inhibitors
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
EP2875013B1 (en) * 2012-07-17 2017-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Indolecarbonitriles as selective androgen receptor modulators
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
AU2015260349B2 (en) 2014-05-14 2019-02-21 Nissan Chemical Industries, Ltd. Tricyclic compound and JAK inhibitor
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
AU2017221193B2 (en) * 2016-02-16 2019-03-14 Zoetis Services Llc Process for preparing 7H-pyrrolo (2, 3-d) pyrimidine compounds
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439010A (zh) * 2000-06-26 2003-08-27 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物作为免疫抑制剂
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW505646B (en) * 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
KR100678800B1 (ko) 2002-11-21 2007-02-05 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1725562A1 (en) 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd Pyrrolopyrimidine derivatives
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CA2614907C (en) 2005-07-29 2012-02-28 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
EP2532667A1 (en) 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
CA2644809A1 (en) * 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439010A (zh) * 2000-06-26 2003-08-27 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物作为免疫抑制剂
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL P.CLARK,等: "Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
CN103896946A (zh) * 2012-12-28 2014-07-02 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
CN107089985B (zh) * 2013-02-22 2019-06-07 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物
CN107089985A (zh) * 2013-02-22 2017-08-25 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
CN105008362B (zh) * 2013-02-22 2017-06-06 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
CN105164133B (zh) * 2013-05-02 2018-02-13 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2，3‑d]嘧啶衍生物
CN105164133A (zh) * 2013-05-02 2015-12-16 豪夫迈·罗氏有限公司 作为CB2受体激动剂的吡咯并[2，3-d]嘧啶衍生物
CN111499641A (zh) * 2019-01-30 2020-08-07 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
US12509463B2 (en) 2019-01-30 2025-12-30 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
CN114025758A (zh) * 2019-07-01 2022-02-08 钱立刚 P2x7r拮抗剂
CN114761011A (zh) * 2019-08-26 2022-07-15 肯沃斯公司 用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物
US12492204B2 (en) 2019-08-26 2025-12-09 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors
CN115246833A (zh) * 2021-04-27 2022-10-28 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法
CN115246833B (zh) * 2021-04-27 2024-08-13 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Also Published As

Publication number Publication date
MX2012004379A (es) 2012-06-01
ES2426407T3 (es) 2013-10-23
CR20120164A (es) 2012-11-07
MA33670B1 (fr) 2012-10-01
JP5629324B2 (ja) 2014-11-19
TW201125866A (en) 2011-08-01
US20110136765A1 (en) 2011-06-09
NI201200053A (es) 2012-08-09
IL218802A0 (en) 2012-06-28
CA2776028C (en) 2015-12-01
TN2012000146A1 (fr) 2013-09-19
PE20121077A1 (es) 2012-08-10
CU20120059A7 (es) 2012-06-29
WO2011045702A1 (en) 2011-04-21
US8633206B2 (en) 2014-01-21
ECSP12011855A (es) 2012-06-29
EP2488524B1 (en) 2013-07-03
DOP2012000080A (es) 2012-06-15
AU2010308028A1 (en) 2012-04-19
TWI398444B (zh) 2013-06-11
JP2013508266A (ja) 2013-03-07
EA201290147A1 (ru) 2012-11-30
KR20120083452A (ko) 2012-07-25
CL2012000795A1 (es) 2012-09-07
CA2776028A1 (en) 2011-04-21
ZA201202718B (en) 2012-12-27
UY32947A (es) 2011-05-31
IN2012DN02577A (enExample) 2015-08-28
PH12012500583A1 (en) 2012-10-22
AR078635A1 (es) 2011-11-23
AP2012006192A0 (en) 2012-04-30
CO6531451A2 (es) 2012-09-28
EP2488524A1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CN102574860A (zh) 吡咯并[2,3-d]嘧啶化合物
EP2513114B1 (en) Pyrrolo[2,3-d]pyrimidine compounds
JP7394820B2 (ja) Ｊａｋ１選択的阻害剤
ES2744636T3 (es) Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína quinasa 1 D/E
JP7471348B2 (ja) ブルトン型チロシンキナーゼの阻害剤及びその使用方法
TWI507408B (zh) 吡咯並［２，３－ｄ］嘧啶衍生物
ES2928757T3 (es) Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
MD3519401T2 (ro) Modulator al regulatorului de conductanță transmembranară în fibroza chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
KR20200096261A (ko) 설폰아마이드 화합물 및 이의 용도
JP2021500339A (ja) タンパク質キナーゼ阻害剤としての複素環化合物
EP3166608A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
CN117999265A (zh) 取代的融合双环大环化合物及其相关治疗方法
JP2022534510A (ja) ヤヌスキナーゼ１の阻害のための新規化合物
JP2019512534A (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
HK1172621A (en) Pyrrolo[2,3-d] pyrimidine compounds
OA19370A (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator.
HK40023760B (zh) 磺酰胺化合物及其用途
HK1243063B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2，3-d]嘧啶衍生物
HK1243063A1 (en) Pyrrolo [2, 3-d] pyrimidine derivatives as inhibitors of janus-related kinases (jak)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711